Andere Kunden interessierten sich auch für
![Improving the Regulatory Review Process]( "Improving the Regulatory Review Process")
Improving the Regulatory Review Process59,99 €![Drug Discovery and Traditional Chinese Medicine]( "Drug Discovery and Traditional Chinese Medicine")
Drug Discovery and Traditional Chinese Medicine191,99 €![Steroid Contraceptives and Women's Response:]( "Steroid Contraceptives and Women's Response:")
Steroid Contraceptives and Women's Response:59,99 €![Quality of Life Assessment]( "Quality of Life Assessment")
Quality of Life Assessment197,99 €![Miraculous Medicines and the Chemistry of Drug Design]( "Miraculous Medicines and the Chemistry of Drug Design")
Miraculous Medicines and the Chemistry of Drug Design82,99 €![Access to Medicines as a Human Right]( "Access to Medicines as a Human Right")
Access to Medicines as a Human Right89,99 €![Influencing factors of medicines use by consumers in Tiko, Cameroon]( "Influencing factors of medicines use by consumers in Tiko, Cameroon")
Influencing factors of medicines use by consumers in Tiko, Cameroon36,99 €
There is currently limited acceptance of foreign clinical data by regulatory authorities, although the reasons for repeating studies are poorly defined. There are some proven genetic differences in drug metabolism and elimination which occur with varying frequencies in different populations. In addition, there are differences in culture, environment and medical practice which can impact on drug reponsiveness.
This book, a further edition in the CMR Workshop Series, reviews the proceedings of a workshop held in London in July 1993 to address these issues. The contributors review the current situation, address the scientific basis for repeating clinical trials in different ethnic groups, consider specific examples, and assess the relevance of interethnic and environmental differences in responsiveness for drug development.
This book, a further edition in the CMR Workshop Series, reviews the proceedings of a workshop held in London in July 1993 to address these issues. The contributors review the current situation, address the scientific basis for repeating clinical trials in different ethnic groups, consider specific examples, and assess the relevance of interethnic and environmental differences in responsiveness for drug development.